Glufosfamide (β-D-glucosyl-ifosfamide mustard) is a new agent for cancer chemotherapy. Its pharmacology is similar to commonly used oxazaphosphorines, but it does not require activation by hepatic cytochrome P-450 and preclinically demonstrates lower nephrotoxicity and myelosuppression than ifosfamide. The aim of the study was a comparison of the drug resistance profiles of glufosfamide and other oxazaphosphorines in childhood acute leukemias. Leukemic cells, taken from children with ALL on diagnosis (n = 41), ALL on relapse (n = 12) and AML on diagnosis (n= 13) were analyzed by means of the MTT assay. The following drugs were tested: glufosfamide (GLU), 4-HOO-ifosfamide (IFO), 4-HOO-cyclophosphamide (CYC) and mafosfamide cyclohexylamine salt (MAF). In the group of initial ALL samples median cytotoxicity values for GLU, IFO, CYC and MAF were 15.5, 33.8, 15.7 and 7.8 μM, respectively. In comparison with initial ALL samples, the relative resistance for GLU and IFO in relapsed ALL samples was 1.9 (p = 0.049) and 1.3 (ns), and in initial AML samples 31 (p < 0.001) and 5 (p = 0.001), respectively. All oxazaphosphorines presented highly significant cross-resistance. Glufosfamide presented high activity against lymphoblasts both on diagnosis and on relapse.
The objective of this study was to evaluate the diagnostic accuracy of sonoelastography in patients of primary and secondary health care settings. Google scholar, PubMed, Medline, Medscape, Wikipedia and NCBI were searched in October 2017 for all original studies and review articles to identify the relevant material. Two reviewers independently selected articles for evaluation of the diagnostic accuracy of sonoelastography in different diseases based on titles and abstracts retrieved by the literature search. The accuracy of sonoelastography in different diseases was used as the index text, while B-mode sonography, micro pure imaging, surgery and histological findings were used as reference texts. Superficial lymph nodes, neck nodules, malignancy in thyroid nodules, benign and malignant cervical lymph nodes, thyroid nodules, prostate carcinoma, benign and malignant breast abnormalities, liver diseases, parotid and salivary gland masses, pancreatic masses, musculoskeletal diseases and renal disorders were target conditions. The data extracted by the two reviewers concerning selected study characteristics and results were presented in tables and figures. In total, 46 studies were found for breast masses, lymph nodes, prostate carcinoma, liver diseases, salivary and parotid gland diseases, pancreatic masses, musculoskeletal diseases and renal diseases, and the overall sensitivity of sonoelastography in diagnosing all these diseases was 83.14% while specificity was 81.41%. This literature review demonstrates that sonoelastography is characterized by high sensitivity and specificity in diagnosing different disorders of the body.
PL
Celem badania była ocena dokładności diagnostycznej sonoelastografii u chorych leczonych w warunkach placówek podstawowej i specjalistycznej opieki zdrowotnej. W październiku 2017 roku dokonano przeglądu baz danych Google Scholar, PubMed, MEDLINE, Medscape, Wikipedia oraz NCBI w celu pozyskania prac oryginalnych i poglądowych, które stanowiły materiał do badania. Prace wybierało dwóch badaczy niezależnie. Oceniono dokładność sonoelastografii w diagnostyce różnych chorób na podstawie tytułów i streszczeń wyszukanych prac. Główny termin stanowiła „skuteczność sonoelastografii w diagnostyce różnych chorób”, a terminy „ultrasonografia w trybie B-mode”, „obrazowanie MicroPure”, „zabieg operacyjny” i „wynik badania histopatologicznego” stosowano jako terminy referencyjne. Badane patologie dotyczyły: powierzchownych węzłów chłonnych, guzków okolicy szyi, złośliwych guzów tarczycy, łagodnych i złośliwych zmian w węzłach chłonnych szyjnych, guzków tarczycy, raka gruczołu krokowego, łagodnych i złośliwych zmian w piersiach, chorób wątroby, zmian w śliniankach przyusznych i gruczołach ślinowych, zmian w trzustce, chorób układu mięśniowo-szkieletowego oraz chorób nerek. Pozyskane przez dwóch badaczy dane dotyczące charakterystyki ocenianych prac oraz wyniki analizy przedstawiają tabele i ryciny. W sumie wyszukano 46 badań dotyczących zmian w piersiach, węzłów chłonnych, raka gruczołu krokowego, chorób wątroby, chorób gruczołów ślinowych i ślinianek przyusznych, zmian w trzustce, chorób układu mięśniowo-szkieletowego i chorób nerek, a ogólna czułość i swoistość sonoelastografii w diagnostyce tych chorób wynosiły odpowiednio 83,14% i 81,41%. Niniejszy przegląd literatury wskazuje na wysoką czułość i swoistość sonoelastografii w diagnostyce różnych chorób. Artykuł w wersji polskojęzycznej jest dostępny na stronie http://jultrason.pl/index.php/issues/volume-18-no-72
Introduction: Colonoscopy and PET / CT are among the major diagnostic tests for colorectal cancer. The sensitivity, specificity, and accuracy of these studies are still being assessed differently. Objective: The aim of the study was to compare the sensitivity, specificity and accuracy of colonoscopy and PET / CT in the diagnosis of colorectal cancer. Material and methods: The medical records of 125 patients with colonoscopy and PET / CT in the years 2014-2015 were analyzed retrospectively. The research was done at the Professor Franciszek Łukaszczyk Oncology Center in Bydgoszcz. Based on the macroscopic description of colonoscopy, the results were divided into two groups: with and without probability of cancer. The average SUV value in PET / CT for colorectal cancer was calculated and without this diagnosis. The average value of SUV 14 and higher was considered probable, while 11 or less had no probability of cancer. Standardized mathematical formulas were used to evaluate the sensitivity, specificity and accuracy. Results: More than half of the patients - 78 (62.4%) were males. The majority of patients -42 (36.6%) were aged 65-74. The majority (106) (68.8%) were diagnosed as polyps and 24 (15.6%) as tumor-like lesions. Polyps were placed in the rectum -32 (30.2%), in the sigmoid colon - 26 (24.5%) and 15 (13.2%) in the ascending colon. Tumors were located in the rectum - 11 (45.8%) and 4 (16.7%) in the recto-sigmoid junction. 38 (24.6%) adenocarcinomas and 67 (43.5%) adenomas were diagnosed. The detection rate of RJG was 32% in colonoscopy and PET / CT. The sensitivity of the colonoscopy was 80%, the specificity - 68.4% and the accuracy - 71.4%. The sensitivity, specificity and accuracy of PET / CT were 65%, 75%, 4% and 72.7%, respectively. Conclusions: Colonoscopy has a higher sensitivity in colorectal cancer diagnosis, but specificity and accuracy are higher in PET / CT. Keywords: colorectal cancer, colonoscopy, PET / CT, sensitivity, specificity, accuracy
In vitro antileukemic activity of five glucocorticoids and their cross-resistance pattern in childhood acute lymphoblastic and non-lymphoblastic leukemia were determined by means of the MTT assay in 25 leukemia cell samples of childhood acute leukemias. The equivalent antileukemic concentrations of the drugs tested were: 34 μM hydrocortisone (HC), 8 μM prednisolone (PRE), 1.5 μM methylprednisolone (MPR), 0.44 μM dexamethasone (DX) and 0.22 μM betamethasone (BET). In comparison with initial ALL cell samples, the relapsed ALL group was more resistant to PRE (38-fold, p = 0.044), DX (> 34-fold, p = 0.04), MPR (38-fold), BET (45-fold) and HC (33-fold). The AML cell samples were even more resistant to: PRE (>85-fold, p=0.001), DX (> 34-fold, p = 0.004), MPR (> 69-fold, p = 0.036), BET (> 69-fold, p = 0.038) and HC (54-fold, p = 0.059) when compared with ALL on initial diagnosis. A significant cross-resistance among all the glucocorticoids used was found. Only in some individual cases the cross-resistance was less pronounced.
Since the 1970s we are witnessing a continuing search for new markers that would assist in the treatment and follow- up of patients with malignant tumors. First reports on benefits of assessment of tumor markers authored by Goldman and Freedman date back to 1965. Discovery of the first carcinoembryonic antigen (CEA) initiate an era of search for substances, still insufficiently sensitive and specific as to be used to screen tumors, but increasingly helpful in the assessment of treatment effects. This paper discusses the role of tumor markers, increasingly often referred to as “classic” in the monitoring of tumors. We present an update on markers with the longest history in oncology practice, e.g. CEA and on the recently introduced marker TATI. Selection of markers was made based on their role in three basic processes taking place in tumor cells, i.e. proliferation, differentiation and apoptosis. We highlight novel and expanding fields of research – genomics and proteomics, which appear to be the future of oncology. They are extremely useful in the evaluation of molecular prognostic factors, enabling implementationof individually tailored targeted therapies in cancer patients. We discuss classic markers and the few known cancer- specific substances. To sum-up, we state that understanding of the role of more sensitive and more specific markers in oncology may contribute to a more personalized treatment and thus may improve the outcome in cancer patients.
PL
Od lat siedemdziesiątych XX wieku nieustannie poszukuje się nowych markerów, które mogą być pomocne w leczeniu i kontroli po jego ukończeniu u chorych na nowotwory złośliwe. Po raz pierwszy przydatność określania markerów nowotworowych opisali Goldman i Freedman w 1965 roku. Oznaczyli pierwszy marker CEA (karcynoembrionalny) i tak zapoczątkowali erę odkryć substancji o wciąż niezadowalającej czułości i swoistości, aby mogły być używane do skriningu chorób nowotworowych, lecz coraz bardziej przydatnych w ocenie efektu leczenia. W pracy opisano zastosowanie markerów nowotworowych coraz częściej określanych mianem klasycznych w procesie śledzenia chorób nowotworowych. Zaprezentowano najnowsze informacje o markerach najdłużej stosowanych w praktyce onkologicznej, na przykład CEA, jak również o nowo wykorzystywanym markerze TATI. Doboru markerów dokonano na podstawie ich udziału w trzech procesach toczących się w komórkach nowotworowych: proliferacji, różnicowaniu i obumieraniu komórek. Zwrócono uwagę na rozwijające się nowe dyscypliny nauki – genomikę i proteomikę, stanowiące przyszłość onkologii. Są one niezwykle pomocne w określeniu molekularnych czynników predykcyjnych umożliwiających stosowanie leczenia celowanego u chorych na nowotwory złośliwe. Opisano markery klasyczne, a także nieliczne markery molekularne występujące w różnych nowotworach. W podsumowaniu stwierdzono, że poznanie natury markerów o znaczącej czułości i swoistości w chorobach nowotworowych może wpłynąć na personalizację leczenia i tą drogą na poprawę wyleczeń chorych na nowotwory złośliwe.
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.